EUVIMEDEUVIMED entdecken
Crossref

Designer benzodiazepines: an update

Xiao Yu, H Karl Greenblatt, David J Greenblatt

Expert Review of Clinical Pharmacology · 01.02.2023 · 16 (2) · 109-117

DOI: 10.1080/17512433.2023.2170349 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 27.01.2023. Verfasst von Xiao Yu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Program in Pharmacology and Drug Development, Tufts University School of Medicine and Graduate School of Biomedical Sciences, Boston, MA, USA. Hauptthemen laut MEDLINE: Central Nervous System Stimulants, Illicit Drugs, Hallucinogens. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 78 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Designer benzodiazepines (DBs) are a subclass of novel psychoactive substances (NPS). DBs mimic the properties of approved and prescribed benzodiazepines. AREA COVERED: A systematic search of literature on DB classification, structure-activity relationships, pharmacologic properties, and adverse effects. EXPERT OPINION: The prevalence of DB use has increased substantially over the last decade. All DBs are full-agonist ligands at the gamma-aminobutyric acid type A-benzodiazepine (GABAA-BZ) receptor system. This is not surprising, since DBs largely represent either minor structural modifications, or well-recognized active metabolites, of existing approved benzodiazepines. As such, the pharmacologic profile and associated risks and hazards of DBs are similar or identical to clinically approved and legitimately prescribed benzodiazepines, most of which have been in use for decades. Concurrent use of DBs along with other abusable or recreational drugs (alcohol, opioids, cocaine, stimulants, hallucinogens, other sedative-hypnotics) represents the principal public health risk. The increasing illicit availability and use of DBs is of concern and requires regulatory attention, but DBs do not rank highly among designer psychotropic agents in terms of health risk to humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Nervous System StimulantsIllicit DrugsHallucinogensHumansBenzodiazepinesPsychotropic Drugs

Stichwörter der Autor:innen

Designer benzodiazepine (DBs)gamma-aminobutyric acid type A-benzodiazepine (GABAA-BZ) agonisthealth risksnovel psychoactive substances (NPS)

Substanzen

BenzodiazepinesPsychotropic DrugsCentral Nervous System StimulantsIllicit DrugsHallucinogens

Autor:innen und Institutionen

  • Program in Pharmacology and Drug Development, Tufts University School of Medicine and Graduate School of Biomedical Sciences, Boston, MA, USA.

Zitieren

APA

Yu, X., Greenblatt, H. K., & Greenblatt, D. J. (2023). Designer benzodiazepines: an update. Expert Review of Clinical Pharmacology, 16(2), 109-117. https://doi.org/10.1080/17512433.2023.2170349

Vancouver

Yu X, Greenblatt HK, Greenblatt DJ. Designer benzodiazepines: an update. Expert Review of Clinical Pharmacology. 2023;16(2):109-117. doi:10.1080/17512433.2023.2170349

BibTeX
@article{Yu2023,
  author = {Yu, Xiao and Greenblatt, H Karl and Greenblatt, David J},
  title = {Designer benzodiazepines: an update},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2023},
  volume = {16},
  number = {2},
  pages = {109--117},
  doi = {10.1080/17512433.2023.2170349}
}
Kostenlos starten →